Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
Date:8/20/2008

NEW YORK, Aug. 20 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation (Nasdaq: GNBT). The full 64-page report can be found at http://www.crystalra.com.

Generex Biotechnology Corporation ("Generex" or "the Company") is a specialty pharmaceutical company that aims to research, develop, and commercialize drug delivery systems and technologies to treat autoimmune disorders, cancers, and infectious and metabolic diseases. Generex's RapidMist(TM) platform technology is a device and liquid formulation combination that can deliver medications to the bloodstream via the buccal mucosa at an improved absorption rate. This formulation is partially composed of absorption enhancers, called surfactants, which enable the oral delivery of a range of compounds, including macromolecules. While the device's appearance is similar to a pulmonary inhaler, the technology differs greatly. Traditional inhalers deliver medication into the lungs; RapidMist(TM) delivers larger-sized molecules into the buccal mucosa of the mouth, with no lung deposition.

The Company's lead product, Generex Oral-lyn(TM), is a buccal insulin spray that uses the RapidMist(TM) platform to treat Type 1 and Type 2 diabetes, which has demonstrated safety and efficacy in clinical trials. Generex Oral-lyn(TM) is currently approved in Ecuador and India. Generex has enrolled over 150 patients in a Phase III trial of Generex Oral-lyn(TM) at 39 clinical sites worldwide. The Company is also developing MetControl(TM) gum to avoid some of the adverse side effects associated with generic metformin tablets. This product candidate could have a shorter path to commercialization as metformin is already an established standard of care for Type 2 diabetes. Generex's wholly owned subsidiary, Antigen Express, Inc., develops prophylactic, immunotherapeutic, and diagnostic candidates through proprietary platform technologies that modulate the immune system to elicit specific responses. Antigen Express's most advanced compound is a breast cancer vaccine in Phase II trials with the U.S. Military Cancer Institute's Clinical Trials Group. In August 2008, Generex began enrolling patients in a Phase I breast and ovarian cancer trial using two immunotherapeutic vaccines designed to function in concert.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Silicon photonic crystals key to optical cloaking, researchers say
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
3. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
4. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
5. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
6. DNA technique yields 3-D crystalline organization of nanoparticles
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. 3-D photonic crystals will revolutionize telecommunications
9. Recombinant Human Renin - Crystallographic Grade
10. UC Riverside researcher develops novel method to grow human embryonic stem cells
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):